通策医疗
(600763)
| 流通市值：164.24亿 | | | 总市值：164.24亿 |
| 流通股本：4.47亿 | | | 总股本：4.47亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 755,289,213.29 | 2,913,101,528.81 | 2,290,207,568.44 | 1,448,440,275.71 |
| 营业收入 | 755,289,213.29 | 2,913,101,528.81 | 2,290,207,568.44 | 1,448,440,275.71 |
| 二、营业总成本 | 528,626,816.22 | 2,250,412,202.89 | 1,651,816,530.61 | 1,060,903,412.94 |
| 营业成本 | 423,913,486.89 | 1,787,821,316.6 | 1,335,438,505.26 | 858,203,094.57 |
| 税金及附加 | 471,767.78 | 6,289,468.05 | 3,878,991.25 | 3,596,189.92 |
| 销售费用 | 8,336,413.6 | 34,351,540.07 | 26,893,168.81 | 14,626,161.95 |
| 管理费用 | 75,243,505.75 | 319,798,633.81 | 210,573,219.19 | 139,096,742.92 |
| 研发费用 | 12,428,842.04 | 61,227,083.26 | 43,104,425.6 | 24,306,610.74 |
| 财务费用 | 8,232,800.16 | 40,924,161.1 | 31,928,220.5 | 21,074,612.84 |
| 其中:利息费用 | 6,426,838.25 | 35,845,027.22 | 30,329,425.2 | 18,445,535.45 |
| 其中:利息收入 | 348,152.51 | 1,958,856.57 | 1,565,100.52 | 1,196,560.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 898,358.23 | - | - |
| 加:投资收益 | 8,806,004.91 | 46,432,488.04 | 41,224,289 | 27,091,151.24 |
| 资产处置收益 | 1,123.48 | -268,751.22 | -172,253.77 | -123,661.68 |
| 资产减值损失(新) | - | -4,236.37 | - | - |
| 信用减值损失(新) | 3,876,212.9 | -11,983,070.21 | -295,791.35 | 85,248.23 |
| 其他收益 | 2,799,328.33 | 10,247,937.97 | 7,767,537.61 | 6,604,894.25 |
| 四、营业利润 | 242,145,066.69 | 708,012,052.36 | 686,914,819.32 | 421,194,494.81 |
| 加:营业外收入 | 44,049.65 | 1,019,133.31 | 110,482.34 | 79,552.78 |
| 减:营业外支出 | 436,747.74 | 3,675,400.47 | 2,783,978.26 | 1,352,515.75 |
| 五、利润总额 | 241,752,368.6 | 705,355,785.2 | 684,241,323.4 | 419,921,531.84 |
| 减:所得税费用 | 21,172,234.05 | 117,065,814.39 | 67,833,713.85 | 39,619,598.06 |
| 六、净利润 | 220,580,134.55 | 588,289,970.81 | 616,407,609.55 | 380,301,933.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 220,580,134.55 | 588,289,970.81 | 616,407,609.55 | 380,301,933.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 186,874,603.48 | 501,945,804.29 | 513,500,420.93 | 321,157,553.42 |
| 少数股东损益 | 33,705,531.07 | 86,344,166.52 | 102,907,188.62 | 59,144,380.36 |
| 扣除非经常损益后的净利润 | 184,827,971.65 | 495,889,571.01 | 508,923,575.3 | 317,346,600.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.42 | 1.12 | 1.15 | 0.72 |
| (二)稀释每股收益 | 0.41 | 1.12 | 1.15 | 0.72 |
| 八、其他综合收益 | -0.12 | -94,310,428.95 | 4,635,380.15 | 3,251,806.45 |
| 归属于母公司股东的其他综合收益 | -0.12 | -94,310,428.95 | 4,635,380.15 | 3,251,806.45 |
| 九、综合收益总额 | 220,580,134.43 | 493,979,541.86 | 621,042,989.7 | 383,553,740.23 |
| 归属于母公司股东的综合收益总额 | 186,874,603.36 | 407,635,375.34 | 518,135,801.08 | 324,409,359.87 |
| 归属于少数股东的综合收益总额 | 33,705,531.07 | 86,344,166.52 | 102,907,188.62 | 59,144,380.36 |
| 公告日期 | 2026-04-18 | 2026-04-18 | 2025-10-28 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |